Fil LTD Mirati Therapeutics, Inc. Transaction History

Fil LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$41.99 - $62.38 $254,543 - $378,147	6,062 Added 8.74%	75,446 $4.43 Million
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $443,410 - $723,332	15,950 Added 29.85%	69,384 $3.02 Million
Q2 2023 Aug 11, 2023	BUY	$36.13 - $49.49 $1.93 Million - $2.64 Million	53,434 New	53,434 $1.93 Million
Q1 2020 May 14, 2020	SELL	$69.78 - $116.21 $4,535 - $7,553	-65 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$70.76 - $128.86 $4,599 - $8,375	65 New	65 $8,000
Q2 2019 Aug 13, 2019	SELL	$59.49 - $104.71 $3.39 Million - $5.98 Million	-57,065 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$43.65 - $78.95 $2.49 Million - $4.51 Million	57,065 New	57,065 $4.18 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

Stay updated on Fil LTD with notifications on news.